Long Essay: Sensorineural Hearing Loss - Cochlear vs. Retrocochlear, Presbycusis, Noise-Induced Hearing Loss, and Sudden SNHL

PART I: COCHLEAR vs. RETROCOCHLEAR HEARING LOSS

Introduction

Pathophysiology

• Reduced sensitivity (elevated pure-tone thresholds)
• Recruitment - an abnormally rapid growth of loudness with increasing intensity, arising because the compressive nonlinearity of the OHC amplifier is lost. Once threshold is reached, loudness grows steeply.
• Distortion of incoming signals, though usually minimal and predictable in degree.
• Reduced frequency selectivity and reduced speech discrimination (largely predictable from the degree of threshold shift).

• May produce elevated thresholds, but can also spare threshold sensitivity (especially with brainstem lesions)
• Causes disproportionately poor speech discrimination relative to pure-tone thresholds - speech perception is affected out of proportion to what the audiogram predicts
• Decruitment - an abnormally slow growth of loudness with increasing intensity (opposite of cochlear recruitment)
• Abnormal auditory adaptation (tone decay) - the auditory signal becomes inaudible far more rapidly than normal, even at suprathreshold levels, owing to failure of VIII nerve neurons to maintain firing rates
• Severe distortion of incoming speech signals, limiting the usefulness of residual hearing

Clinical Features

Audiological Tests for Differentiation

• In cochlear loss: tympanogram normal, acoustic reflex thresholds are present at reduced sensation levels (reflecting recruitment) - the acoustic reflex occurs at a lower sensation level (SL) than in normal ears. This is the basis of SPAR (Sensitivity Prediction by the Acoustic Reflex).
• In retrocochlear loss: acoustic reflex thresholds are elevated or absent at intensity levels out of proportion to the degree of hearing loss. If behavioral thresholds are mild-moderate but reflexes are absent or markedly elevated, this strongly suggests retrocochlear pathology.
• Reflex decay test: When the acoustic reflex is sustained for 10 seconds, amplitude decay of >50% within 5 seconds is abnormal (positive reflex decay = retrocochlear).

• In cochlear loss: SDS (speech discrimination score) is reduced but proportional to the degree of threshold shift. A PB word score of ~80-90% is expected with mild cochlear loss.
• In retrocochlear loss: SDS is disproportionately poor - a patient with a mild hearing loss may have a word recognition score of 20-30%, which could not be explained by threshold elevation alone.
• Rollover: When PB scores are plotted against intensity (PI-PB function), a decline in score at high intensities (>45% decline = rollover) strongly suggests retrocochlear pathology (Cummings Otolaryngology, block 34).

• Cochlear loss: ABR shows prolonged absolute latencies (consistent with degree of hearing loss) but normal interwave intervals (I-III, III-V, I-V). Wave V latency is delayed in proportion to the threshold.
• Retrocochlear loss: ABR shows prolonged interwave intervals, particularly I-V interwave interval >4.4 ms, interaural wave V latency difference >0.2 ms, poor waveform morphology, or absent wave I-III. ABR has historically been considered the gold standard test for retrocochlear pathology.
• However, ABR has reduced sensitivity for small vestibular schwannomas (<1 cm) and has been largely replaced by MRI for this purpose (Cummings Otolaryngology).

• OAEs are generated by the cochlea (specifically the OHCs) and are a direct measure of cochlear function.
• In cochlear hearing loss >30-35 dB: OAEs are typically absent.
• In retrocochlear loss: OAEs may be present (preserved) even in the face of elevated thresholds and poor speech discrimination - because the cochlea itself is intact and the problem lies in the nerve. This "OAE present + poor ABR/speech discrimination" dissociation is highly characteristic of retrocochlear or auditory neuropathy spectrum disorder.
• However, a retrocochlear disorder can also secondarily affect cochlear function (retrograde degeneration), resulting in absent OAEs.

• Cochlear loss: threshold tone decay is minimal (<10 dB)
• Retrocochlear: pathological decay (>25-30 dB) because auditory nerve fibers cannot maintain sustained firing

• Cochlear: high SISI score (80-100%) - detects 1 dB increments at suprathreshold levels due to recruitment
• Retrocochlear: low SISI score (<20%)

• Type II pattern (cochlear): interrupted and continuous tone tracings separate slightly at high frequencies
• Type III/IV pattern (retrocochlear): continuous tone tracing falls markedly below interrupted, indicating rapid adaptation

Clinical Red Flags Warranting MRI

• Asymmetric SNHL (>15 dB at 2 adjacent frequencies)
• Unilateral tinnitus
• Disproportionately poor or asymmetric speech discrimination score
• Absent or elevated acoustic reflexes inconsistent with degree of loss
• Abnormal ABR (prolonged I-V interval)
• Associated neurological symptoms: facial numbness/weakness, dysequilibrium, headache
• PI-PB rollover on speech audiometry

PART II: PRESBYCUSIS (Age-Related Hearing Loss)

Definition

Epidemiology

• Affects approximately 30-35% of adults over 65 years; rises to 40-50% by age 75.
• More severe in men than in women.
• Progressive, typically bilateral and symmetric.
• High-frequency consonants are most affected, leading to disproportionate difficulty with speech discrimination despite apparently modest threshold elevation.

Pathophysiology and Types (Schuknecht's Classification)

• Pathology: Progressive degeneration and loss of outer hair cells (OHCs), beginning at the basal turn of the cochlea (which encodes high frequencies).
• Audiogram: Steeply downsloping high-frequency SNHL.
• Speech discrimination: Relatively preserved (loss correlates with threshold shift).
• Onset: Early adulthood, slow progression.

• Pathology: Degeneration of auditory nerve fibers (spiral ganglion cells). Cochlear sensory cells may be relatively preserved.
• Audiogram: May show variable configuration.
• Speech discrimination: Disproportionately poor relative to pure-tone thresholds - the hallmark of neural presbycusis. This is because auditory neurons are critical for fine temporal processing and speech encoding.
• Note: This pattern overlaps with retrocochlear loss; the difference is that neural presbycusis is bilateral and degenerative rather than focal and structural.

• Pathology: Atrophy of the stria vascularis - the structure responsible for maintaining the endocochlear potential and endolymph composition. Reduces endocochlear potential.
• Audiogram: Flat audiogram across all frequencies (not just high frequencies), because the energy supply to the entire cochlea is impaired.
• Speech discrimination: Relatively well preserved (the cochlear mechanics are intact).
• Prognosis: Most favorable for hearing aid use.

• Pathology: Theorized increase in basilar membrane stiffness or alteration in its mechanical properties.
• Audiogram: Gradually descending (linear) slope across all frequencies.
• This type is largely a theoretical construct inferred from audiometric patterns not explained by the other three types.

Clinical Features

• Gradual, bilateral, symmetric SNHL
• Predominant high-frequency loss (typically >2 kHz first affected)
• Tinnitus - frequently accompanies presbycusis
• Difficulty with speech discrimination in background noise (may be the chief complaint, even with near-normal audiogram)
• Consonants (f, s, sh, th, k) lie in the high-frequency range and are most affected, making conversational speech intelligible in quiet but unintelligible in noise
• Patients often complain that people "mumble" rather than acknowledging hearing difficulty
• Audiogram: typically bilateral, symmetric, sloping high-frequency SNHL. (Bailey and Love's, block 6)

Investigations

• Pure-tone audiogram (PTA): bilateral downsloping SNHL
• Speech discrimination/word recognition scores
• Tympanometry: normal
• OAEs: absent at frequencies with >35 dB hearing loss
• ABR: prolonged absolute latencies proportional to degree of loss; normal interwave intervals
• MRI IAC: if asymmetric or unusual features to exclude retrocochlear pathology

Management

1. Counselling and reassurance - most patients fear complete deafness; reassurance that progression is typically slow is important.
2. Hearing aids - most effective treatment. Digital hearing aids with directional microphones and noise reduction algorithms. Indicated when thresholds exceed 30-40 dB and/or word recognition scores are satisfactory (>50%). Technology has improved dramatically and most patients can derive significant benefit.
3. Cochlear implantation - considered in patients with severe to profound bilateral SNHL with poor word recognition scores (<50%) who receive limited benefit from hearing aids. Age per se is not a contraindication and outcomes in carefully selected elderly patients are favorable.
4. Communication strategies - lip reading, face-to-face communication, reducing background noise.
5. Management of contributing conditions - optimal control of diabetes and vascular risk factors may slow progression.
6. Tinnitus management - tinnitus frequently accompanies presbycusis; treatment includes reassurance, masking, and hearing aids (which reduce tinnitus awareness by amplifying ambient sound).

PART III: NOISE-INDUCED HEARING LOSS (NIHL)

Introduction

Definition and Classification

• Intensity (in dB SPL)
• Time course: continuous, fluctuating, intermittent, impact (collision of objects), impulse (sudden energy release - explosion, gunfire)
• Spectral content: pure tone, narrow-band, broadband

• Caused by repeated exposures to noise of high intensity or long duration
• Each exposure produces a temporary threshold shift (TTS) that recovers in 24-48 hours
• With repeated exposures, a permanent threshold shift (PTS) develops

• Caused by a single exposure to an extremely high level of noise
• Directly results in PTS without an intercurrent TTS
• Examples: blast injury, gunfire, industrial explosion

Pathophysiology

• Reduction of cochlear blood flow
• A cascade of metabolic events with formation of reactive oxygen species (ROS) and reactive nitrogen species
• These damage cellular lipids, proteins, and DNA
• Leading to OHC apoptosis and necrosis

• The basal turn of the cochlea (encoding 3-6 kHz) receives the greatest mechanical energy and is most vulnerable
• This explains the characteristic 4 kHz notch in NIHL

• Inner hair cells (IHC) are damaged
• Spiral ganglion neurons undergo secondary degeneration after hair cell loss

• Direct mechanical shearing of stereocilia
• Glutamate excitotoxicity at the IHC-auditory nerve synapse
• Oxidative stress
• Ischemia-reperfusion injury (Cummings Otolaryngology, block 34 and 35)

Factors Influencing NIHL

1. Sound level (dB SPL)
2. Spectral composition (high-frequency sounds more damaging)
3. Time distribution of exposure during a working day
4. Cumulative exposure over days, weeks, and years

Audiometric Features

• Early NIHL: hearing loss limited to the 3, 4, and 6 kHz range, with a characteristic notch deepest at 4 kHz
• Recovery at 8 kHz is common early in the course ("notch with recovery")
• As exposure continues: lower frequencies become involved, but loss at 3-6 kHz is always disproportionately worse
• Progression is most rapid during the first 10-15 years of exposure, then slows
• Almost always bilateral and symmetric (unlike acoustic trauma which can be unilateral)
• NIHL almost never produces profound hearing loss

• The 4 kHz region corresponds to the region of the cochlea approximately 9-11 mm from the oval window - the area of maximum mechanical stress from the traveling wave generated by complex sounds
• The "half-octave shift" hypothesis: structures encoding 3-4 kHz receive maximum energy from sounds in the 2-3 kHz range (the principal frequency range of speech), due to resonance effects in the external auditory canal

Diagnosis

• History of noise exposure (occupational or recreational)
• Audiogram showing bilateral, symmetric, downsloping SNHL with 4 kHz notch and relative preservation (recovery) at 8 kHz
• Tympanometry: normal
• No spontaneous recovery (unlike TTS, which resolves within 24-48 hours)
• Binaural Hearing Impairment (BHI) calculation (K.J. Lee):
  • PTA for each ear at 0.5, 1, 2, and 3 kHz
  • Monoaural impairment (MI) = 1.5 × (PTA - 25)
  • BHI = [5 × (MI of better ear) + (MI of worse ear)] / 6

Prevention

1. Assessment: Measure noise levels using sound level meters and dosimeters
2. Engineering controls: Reduce noise at source (silencers, damping materials, acoustic barriers, machine enclosures)
3. Administrative controls: Limit duration of exposure, job rotation
4. Ear protection devices (EPDs):
   • Earmuffs, custom-fitted earplugs, or disposable earplugs
   • Provide 20-40 dB of attenuation, more at high frequencies
   • Proper fit, comfort, and motivation are equally important
5. Audiometric monitoring: Pre-employment baseline audiogram, then annual monitoring

Treatment

• No proven treatment exists to restore hearing after established NIHL (PTS)
• Hearing aids: for those with functionally significant loss
• Cochlear implantation: for severe-profound NIHL with poor hearing aid benefit
• Compensation: legal and occupational frameworks exist for documented NIHL

PART IV: SUDDEN SENSORINEURAL HEARING LOSS (SSNHL)

Definition and Diagnostic Criteria

A decrease in hearing of ≥30 dB at 3 or more contiguous audiometric frequencies occurring within a 72-hour period.

Epidemiology

• Incidence: 5-20 per 100,000 persons per year
• Accounts for 2-3% of unselected otologic outpatient visits
• Peak incidence: 6th decade of life
• Male-to-female ratio: equal
• Almost always unilateral - simultaneous bilateral involvement is very rare
• Any age group can be affected

Etiology and Pathogenesis

1. Viral cochleitis/neuritis - most favored theory. Supported by: 28% of patients report preceding URI; elevated viral titers (HSV, CMV, EBV, influenza); mumps virus isolated from perilymph; cochlear histopathology consistent with viral infection
2. Vascular occlusion - cochlear blood supply is end-arterial with no collateral. Labyrinthine artery (a branch of AICA) occlusion produces sudden profound loss. Supported by association with cardiovascular risk factors
3. Intracochlear membrane rupture - Reissner's membrane or basilar membrane tears, causing mixing of endolymph and perilymph, resulting in ion toxicity to the organ of Corti
4. Autoimmune - antibodies against inner ear antigens

Clinical Presentation

• Most common: Patient notices unilateral hearing loss on awakening
• Alternatively: sudden, stable hearing loss or rapidly progressive loss over hours
• Aural fullness - very common and may be the primary complaint (patient may not initially recognize hearing loss)
• Tinnitus - present in the affected ear to a variable degree; may precede the hearing loss
• Vertigo/dysequilibrium - present in approximately 40% of patients; indicates labyrinthine involvement
• SSNHL should be treated as an otologic emergency

Natural History and Prognosis

1. Severity of loss: More severe loss = worse prognosis. Profound losses carry exceptionally poor prognosis.
2. Audiogram shape: Upsloping and midfrequency losses recover better than downsloping or flat losses.
3. Presence of vertigo: A poor prognostic indicator (especially with downsloping loss), suggesting extensive labyrinthine involvement.
4. Age: Children and adults >40 years have worse prognosis than young adults.

• Reduced speech discrimination scores
• Delayed treatment (most recovery occurs within the first 2 weeks)

Investigation

• Full audiological assessment: PTA, speech discrimination, tympanometry, acoustic reflexes
• ABR
• MRI with gadolinium of the IACs and posterior fossa - essential to exclude vestibular schwannoma (1% of acoustic neuromas present as SSNHL) and other structural lesions. This is the most important investigation (Bailey and Love's, block 6).

• FBC, ESR, CRP
• Fasting glucose (diabetes)
• Thyroid function
• Syphilis serology (FTA-ABS, VDRL)
• Viral titres (HSV, EBV, CMV) - of limited yield without clinical suspicion
• Autoimmune screen (ANA, ANCA, antiphospholipid antibodies) - if autoimmune etiology suspected
• Hypercoagulability screen (protein C, S; factor V Leiden) - if vascular etiology suspected

Management

• Most widely accepted treatment
• Rationale: anti-inflammatory and immunomodulatory effects
• Standard regimen: Prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 10-14 days, with gradual taper
• If partial recovery at end of 10 days: extend full dose another 10 days, repeat until no further improvement
• Evidence: Wilson et al. RCT showed 78% complete/partial recovery with steroids vs. 38% with placebo (excluding profound and midfrequency losses). However, two systematic reviews including a Cochrane review concluded effectiveness remains unproven due to methodological limitations and conflicting RCTs.

• Deliver high concentrations directly to the round window membrane - > round window diffusion into perilymph
• Avoids systemic side effects - suitable for patients with diabetes, glaucoma, cataracts, peptic ulcer
• Agents: dexamethasone (1-25 mg/mL) or methylprednisolone (62.5 mg/mL)
• Volume: 0.3-0.5 mL to fill middle ear space
• Primary treatment: Non-inferior to systemic steroids in some RCTs - an option for patients with contraindications to systemic steroids
• Salvage therapy: If oral steroids fail, IT steroids should be given as soon as possible (ideally within first 2 weeks of onset). Meta-analyses demonstrate significant treatment effect for salvage IT steroids. The longer the interval between oral steroid failure and IT rescue therapy, the lower the chance of hearing salvage (Cummings Otolaryngology, block 35).
• Current AAO-HNS guidelines (2012) recommend: offer systemic steroids as initial treatment; offer IT steroids as salvage for incomplete/failed oral steroid response.

• Antivirals (acyclovir) - used empirically (particularly for Ramsay Hunt syndrome/herpes zoster oticus); evidence in idiopathic SSNHL is weak
• Antibiotics for bacterial labyrinthitis
• Withdrawal of ototoxic drugs
• Immunosuppressants for AIED (steroids, methotrexate)
• Anticoagulation for vascular/hypercoagulable etiologies

• Carbogen inhalation (5% CO2 + 95% O2) - theoretically improves cochlear blood flow; not routinely recommended
• Rheological agents (dextran, pentoxifylline, hydroxyethyl starch) - low-molecular-weight dextran has been used in some European centers
• Hyperbaric oxygen therapy (HBOT) - some evidence (particularly within 2-4 weeks of onset) as adjuvant therapy in moderate-severe SSNHL; not yet universally adopted
• Vasodilators (histamine, papaverine): insufficient evidence

• For patients with permanent hearing loss:
  • Hearing aids for mild-moderate loss
  • CROS/BiCROS aids for unilateral profound loss
  • Bone-anchored hearing devices (BAHA)
  • Cochlear implantation for profound bilateral loss

Summary Table: Key Distinguishing Features

References

• Cummings Otolaryngology: Head and Neck Surgery (6th Ed.) - Chapters 152 and 158 (SNHL, NIHL, SSNHL)
• K.J. Lee's Essential Otolaryngology (11th Ed.) - Chapter 14 (NIHL, Presbycusis)
• Shambaugh: Surgery of the Ear (6th Ed.) - Cochlear and Retrocochlear Disorders, Audiometric Evaluation
• Bailey and Love's Short Practice of Surgery (28th Ed.) - Chapter 51 (Presbycusis, SSNHL)
• AAO-HNS Clinical Practice Guideline: Sudden Hearing Loss (2012)
• NIDCD Definition of Sudden SNHL (≥30 dB at 3 contiguous frequencies within 72 hours)

OTOTOXICITY

Definition

Classes of Ototoxic Drugs

1. Aminoglycoside Antibiotics (Most Common)

• Aminoglycosides (AGs) bind to phosphatidylinositol on the hair cell membrane
• They chelate iron, which participates in free radical (ROS) formation
• Cell damage begins in the inner row of outer hair cells (OHCs) at the basal turn of the cochlea, progressing to the remaining two rows over time
• Proceeds in a basal-to-apical direction - explaining why high-frequency SNHL appears first
• Drug levels concentrate and persist in the endolymph long after serum levels fall (endolymph sequestration)
• Histopathology: OHC loss + stria vascularis damage

• Bilateral, permanent, high-frequency SNHL
• Toxicity correlates with serum trough levels above therapeutic range
• Renal dosing and monitoring of kidney function are essential (renal clearance)

• Streptomycin, Gentamicin, Tobramycin - primarily vestibulotoxic
• Kanamycin, Amikacin, Neomycin - primarily cochleotoxic

• A1555G mitochondrial 12S rRNA mutation confers exquisite sensitivity to AG ototoxicity - more common in certain Chinese populations. Affected individuals may sustain profound SNHL even at therapeutic doses.
• Topical aminoglycoside ear drops are hazardous when the tympanic membrane is not intact
• Middle ear AG instillation (buffered gentamicin) is deliberately used for chemical vestibular ablation in Meniere's disease

2. Platinum-based Chemotherapeutic Agents

• Damage OHCs and stria vascularis epithelium of the lateral cochlear wall
• Similar histopathology to aminoglycosides
• ROS-mediated hair cell apoptosis

• Dose-dependent, permanent bilateral SNHL
• Initial loss at 4-8 kHz, progressing to lower frequencies with continued dosing
• SNHL demonstrated in >50% of patients; tinnitus in ~7%
• Clinically significant hearing loss (tinnitus + symptomatic loss) in 15-20%; audiometric changes in up to 75% in some studies (Scott-Brown's)
• Onset is variable: severe loss can occur after a single dose, or symptoms may appear months after the last dose

• Cumulative dose
• Renal failure
• Concurrent use of other ototoxic drugs (aminoglycosides)
• Radiotherapy - synergistic effect, also causes serous otitis media complicating assessment
• Children are especially vulnerable (high-dose regimens, combined with RT or two platinum compounds); consequences for speech and language development are profound

3. Loop Diuretics

• Block the Na⁺-K⁺-2Cl⁻ symporter in the loop of Henle - same transporter present in the stria vascularis
• Cause electrolyte imbalance in the endolymph by blocking the H⁺/K⁺ ATPase of the stria vascularis
• Reduce the endocochlear potential

• Ototoxic effects are typically transient (reversible with drug cessation)
• Risk is highest with rapid intravenous bolus administration; can be minimized by slow IV infusion
• Profound, sudden (but reversible) SNHL can occur with rapid high-dose IV furosemide
• Synergy with aminoglycosides: concurrent furosemide/vancomycin + aminoglycoside is a recognized ototoxic combination of increased risk

4. Quinine / Chloroquine (Antimalarials)

• Primarily cochleotoxic: reversible vasculitis and ischemia of the inner ear
• Degenerative changes in the organ of Corti and stria vascularis

• Usually reversible with drug cessation at standard therapeutic doses
• May cause tinnitus and high-frequency SNHL
• Neonates born to mothers taking these drugs may exhibit bilateral SNHL even if the mother's hearing is unaffected
• Chloroquine ototoxicity is also recognised

5. Salicylates

• Reversible hearing loss and tinnitus - no histopathological hair cell damage demonstrated
• Mechanism may involve reduced cochlear blood flow and inhibition of prostaglandin synthesis
• Dose threshold: >2.7 g/day of ASA required to produce cochlear effects

• Fully reversible once drug is cleared (renally excreted)
• Classic presentation: tinnitus + mild flat SNHL at toxic doses; resolves on cessation
• Does not cause permanent structural damage

6. Other Ototoxic Agents (Summary)

Summary Table: Key Ototoxic Drugs

Risk Factors for Ototoxicity

1. High cumulative dose of ototoxic drug
2. Rapid IV administration (particularly loop diuretics)
3. Renal impairment - reduced drug clearance, elevated serum levels
4. Concurrent ototoxic drugs (synergy - e.g., aminoglycoside + furosemide + vancomycin)
5. Concurrent radiotherapy (synergistic with cisplatin)
6. Age extremes - neonates and elderly especially vulnerable
7. Genetic predisposition - A1555G mitochondrial mutation (aminoglycosides); polymorphisms in cisplatin metabolism
8. Pre-existing hearing loss
9. Duration of therapy

Clinical Features

• Cochleotoxicity: bilateral, symmetric, high-frequency SNHL (basal turn first); tinnitus
• Vestibulotoxicity: oscillopsia, postural instability, bilateral vestibular hypofunction (Dandy's syndrome with streptomycin)
• Onset may be insidious - patient may not notice hearing loss until speech frequencies are affected
• Hearing loss may progress even after drug cessation (continued apoptosis from sequestered drug)

Diagnosis and Monitoring

1. Baseline audiogram before initiating known ototoxic therapy
2. Serial pure-tone audiometry during and after treatment - including extended high-frequency audiometry (8-20 kHz) to detect early subclinical loss
3. DPOAEs - more sensitive than behavioural audiometry for early detection; useful in children <5 years
4. Vestibular function tests (caloric testing, VHIT, vestibular evoked myogenic potentials) when vestibulotoxicity is suspected
5. Drug level monitoring - serum trough levels of aminoglycosides; renal function tests

Management and Prevention

1. Avoid concurrent ototoxic drugs where possible
2. Careful dosing - once-daily dosing of aminoglycosides (lower peak levels, less accumulation in endolymph) may be less ototoxic than multiple daily dosing
3. Slow IV infusion of loop diuretics rather than bolus
4. Dose reduction or cessation when audiometric deterioration is detected
5. Otoprotective agents (under investigation):
   • Sodium thiosulfate - trialed against cisplatin ototoxicity
   • N-acetylcysteine, d-methionine - antioxidants; ROS scavengers
   • No established clinical standard yet
6. Hearing rehabilitation: hearing aids, BAHA, cochlear implantation for permanent SNHL
7. Genetic screening for A1555G mutation before aminoglycoside use (when feasible)
8. Patient counseling: inform patients of risk; instruct to report tinnitus or hearing changes promptly

References

• K.J. Lee's Essential Otolaryngology (11th Ed.), Chapter on Ototoxicity
• Scott-Brown's Otorhinolaryngology, Head & Neck Surgery (8th Ed.), Vol. 1 and Vol. 2
• Cummings Otolaryngology: Head and Neck Surgery (6th Ed.), Chapter 154